随着疾病传播，Mpox测试制造者以巨大的收益结束了这一天

2024-08-20 05:25

Several small diagnostics companies surged in Monday trading as demand for their mpox tests is expected to dramatically increase as cases of the newest variant of the disease have now been reported outside of Africa.
Virax Biolabs (NASDAQ:VRAX) and Applied DNA Sciences (NASDAQ:APDN), with market caps of, respectively, $5M and $8M, closed up 142% and 129%.
Co-Diagnostics (NASDAQ:CODX), which also has a mpox test, rose 26%.
Emergent BioSolutions (EBS), which has a smallpox vaccine that has expanded access status for use in mpox, ACAM2000, closed up ~13%. An application for full approval is before the U.S. FDA and could be granted as soon as this quarter.
Bavarian Nordic (OTCPK:BVNKF)(OTCPK:BVNRY), which produces Jynneos, the only vaccine approved in the U.S. and Europe for mpox, lost ~5% on the day.
Tonix Pharmaceuticals (NASDAQ:TNXP) and GeoVax Labs (GOVX), which are both developing mpox vaccines, had tremendous gains earlier in the trading day. Tonix was up as much as ~89%, but closed down 0.5% while GeoVax was up at its highest ~58% but closed just ~1% higher.

More on mpox stocks